The neuroprotective products market is forecast to accomplish strong revenue growth over the next decade, especially from 2017, with the market set to reach $2.6 billion in 2014. Within five years many clinical trials will have finished and drugs will gain regulatory approval.
Growth within the neuroprotective products market is set to be driven by the rising incidence and prevalence of neurodegenerative diseases in ageing populations, along with the treatment of brain injuries, especially those from traffic accidents.
Neuroprotection is the mechanisms and strategies used to protect against neuronal injury or degeneration in the Central Nervous System (CNS) following acute disorders (e.g. stroke or nervous system injury/trauma) or as a result of chronic neurodegenerative diseases (e.g. Parkinson's, Alzheimer's, Multiple Sclerosis).
The goal of neuroprotection is to limit neuronal dysfunction/death after CNS injury and attempt to maintain the highest possible integrity of cellular interactions in the brain resulting in an undisturbed neural function.
The pharmaceutical industry will develop more treatments for neuronal protection, with high revenues possible this decade and beyond. The main aim of drug developers is to prevent neuronal death and revive damaged neurons (neuroregeneration). Not all neuroprotective agents will be neuroregenerative, however.
For more information on the neuroprotective products market, see the latest research: Neuroprotective Products Market Report
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.